Corbevax, an open-license Covid-19 vaccine that confers protection against multiple Variants of Concern and received emergency use authorization from WHO in January 2024, has a shelf life of 24 months at 2-8°C and is currently being manufactured in a lower middle income country.
- WHO 2024: WHO EUL/PQ status of COVID-19 vaccines
- Hotez 2023: From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access
- Thuluva 2023: Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
The WHO Emergency Listing Procedure has listed COVID-19 vaccine candidates that have received EUL or PQ status, with many able to be stored at 2-8°C for a minimum of 9 months.